{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:55:06Z","timestamp":1791190506858,"version":"4.1.0"},"reference-count":22,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Neurourology and Urodynamics"],"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Urinary retention rates after intradetrusor onabotulinumtoxinA (BTX\u2010A) peak at 2 weeks, yet risk stratification by sex and neurogenic status remains limited. We evaluated predictors of 2\u2010week post\u2010void residual (PVR) and differences by sex and neurogenic bladder status using the largest retrospective cohort to date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We reviewed all BTX\u2010A procedures at a single academic institution from January 2020 to June 2025. Patients younger than 18 years, those with mean preprocedural PVR\u2009\u2265\u2009150\u2009mL, prior pelvic radiation, or preprocedural catheterization requirements were excluded. Two\u2010week PVR was analyzed using multivariable regression of demographics and urodynamic parameters, adjusting for total injections per patient, with subgroup analyses by sex\u2010assigned\u2010at\u2010birth and neurogenic status.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 824 patients underwent 2282 BTX\u2010A injections. The cohort was predominantly female (95.9%) and non\u2010neurogenic (93.7%), with mean preprocedural PVR of 24\u2009mL, mean BTX\u2010A dose of 120.8 units, and mean 2\u2010week PVR of 66.7\u2009mL. Higher preprocedural PVR was associated with higher 2\u2010week PVR among female patients (\u03b2\u2009=\u20090.593\u2009mL, 95% CI [0.303, 0.883]) and non\u2010neurogenic patients (\u03b2\u2009=\u20090.555, 95% CI [0.284, 0.825]), but not among male or neurogenic patients. Higher BTX\u2010A dose was similarly associated with higher 2\u2010week PVR among female patients (\u03b2\u2009=\u200925.7\u2009mL per 100 U, 95% CI [6.16, 45.2]) and non\u2010neurogenic patients (\u03b2\u2009=\u200928.1\u2009mL per 100U, 95% CI [10.5, 45.6]). Lower maximum flow rate (Qmax) was associated with higher 2\u2010week PVR among female patients (\u03b2\u2009=\u2009\u22121.25\u2009mL per mL\/sec, 95% CI [\u22121.94, \u22120.56]), neurogenic patients (\u03b2\u2009=\u2009\u221217.4, 95% CI [\u221231.5, \u22123.26]), and non\u2010neurogenic patients (\u03b2\u2009=\u2009\u22121.08, 95% CI [\u22121.74, \u22120.418]). Higher detrusor pressure at maximum flow (pDet@Qmax) was associated with higher 2\u2010week PVR among female (\u03b2\u2009=\u20090.557\u2009mL\/cmH\n                      <jats:sub>2<\/jats:sub>\n                      O, 95% CI 0.136, 0.979]) and neurogenic patients (\u03b2\u2009=\u20092.68\u2009mL\/cmH\n                      <jats:sub>2<\/jats:sub>\n                      O, 95% CI 0.126, 5.23]), whereas lower pDet@Qmax was associated with higher PVR among male patients (\u03b2\u2009=\u2009\u22128.34\u2009mL\/cmH\n                      <jats:sub>2<\/jats:sub>\n                      O, 95% CI \u221212.9, \u22123.76]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pre\u2010procedural PVR and BTX\u2010A dose were consistent predictors of elevated 2\u2010week PVR in females and non\u2010neurogenic patients. These findings support sex\u2010 and neurogenic\u2010specific risk stratification and dose considerations prior to BTX\u2010A injection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/nau.70473","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:25:26Z","timestamp":1791188726000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictors of 2\u2010Week Post\u2010Void Residual After Intradetrusor OnabotulinumtoxinA Injection for Overactive Bladder: A Sex\u2010 and Neurogenic Status\u2010Stratified Analysis"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3185-7026","authenticated-orcid":false,"given":"Saawan D.","family":"Patel","sequence":"first","affiliation":[{"name":"Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Rosario","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9784-2559","authenticated-orcid":false,"given":"Ariana L.","family":"Smith","sequence":"additional","affiliation":[{"name":"Division of Urology, Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.23477"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003985"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.12.022"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.04.001"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-018-3653-z"},{"key":"e_1_2_12_7_1","volume-title":"Neurourology and Urodynamics","author":"Chapter 6: Practical Aspects of Administration of OnabotulinumtoxinA \u2010 Rovner 2014","year":"2026"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/164_2023_667"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.25538"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2023.09.013"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000032377"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.09.007"},{"key":"e_1_2_12_15_1","unstructured":"Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double\u2010Blind Placebo Controlled Randomized Dose Ranging Trial Journal of Urology. The Journal of Urology. Published online October 18 2010 accessed June 3 2026.https:\/\/www.auajournals.org\/doi\/10.1016\/j.juro.2010.08.021."},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.70050"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/luts.70004"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005991"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208872"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2022.05.003"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-024-06028-3"},{"key":"e_1_2_12_22_1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/nau.70017","article-title":"Variation in the Definitions of Urinary Retention in Studies of Intravesical Botulinum Toxin for Idiopathic Overactive Bladder: A Narrative Systematic Review","volume":"44","author":"Stavrou S.","year":"2026","journal-title":"Neurourology and Urodynamics"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.3390\/toxins17040207"}],"container-title":["Neurourology and Urodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.70473","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/nau.70473","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/nau.70473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:25:28Z","timestamp":1791188728000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/nau.70473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":22,"alternative-id":["10.1002\/nau.70473"],"URL":"https:\/\/doi.org\/10.1002\/nau.70473","archive":["Portico"],"relation":{},"ISSN":["0733-2467","1520-6777"],"issn-type":[{"value":"0733-2467","type":"print"},{"value":"1520-6777","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"2026-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"nau.70473"}}